Seek Returns logo

BIO vs. PHG: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at BIO and PHG, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

BIO is a standard domestic stock, while PHG trades as New York Registered Shares, providing U.S. investors with a way to invest in the foreign-based company.

SymbolBIOPHG
Company NameBio-Rad Laboratories, Inc.Koninklijke Philips N.V.
CountryUnited StatesNetherlands
GICS SectorHealth CareHealth Care
GICS IndustryLife Sciences Tools & ServicesHealth Care Equipment & Supplies
Market Capitalization7.99 billion USD26.57 billion USD
ExchangeNYSENYSE
Listing DateFebruary 27, 1980March 17, 1980
Security TypeCommon StockNY Reg Shrs

Historical Performance

This chart compares the performance of BIO and PHG by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

BIO vs. PHG: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolBIOPHG
5-Day Price Return3.12%2.03%
13-Week Price Return30.92%17.87%
26-Week Price Return4.81%-0.04%
52-Week Price Return-4.08%-12.66%
Month-to-Date Return22.91%4.20%
Year-to-Date Return-9.48%-1.35%
10-Day Avg. Volume0.24M0.96M
3-Month Avg. Volume0.34M1.81M
3-Month Volatility47.19%27.62%
Beta0.991.06

Profitability

Return on Equity (TTM)

BIO

4.58%

Life Sciences Tools & Services Industry

Max
19.96%
Q3
11.55%
Median
6.22%
Q1
3.86%
Min
-6.95%

BIO’s Return on Equity of 4.58% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.

PHG

-0.18%

Health Care Equipment & Supplies Industry

Max
34.53%
Q3
19.38%
Median
9.52%
Q1
4.86%
Min
-7.58%

PHG has a negative Return on Equity of -0.18%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

BIO vs. PHG: A comparison of their Return on Equity (TTM) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

BIO

12.49%

Life Sciences Tools & Services Industry

Max
27.28%
Q3
16.17%
Median
7.24%
Q1
3.00%
Min
-3.05%

BIO’s Net Profit Margin of 12.49% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

PHG

0.90%

Health Care Equipment & Supplies Industry

Max
23.34%
Q3
13.06%
Median
9.53%
Q1
5.96%
Min
-3.87%

Falling into the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Net Profit Margin of 0.90% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

BIO vs. PHG: A comparison of their Net Profit Margin (TTM) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

BIO

8.74%

Life Sciences Tools & Services Industry

Max
33.15%
Q3
19.34%
Median
13.02%
Q1
8.05%
Min
-4.38%

BIO’s Operating Profit Margin of 8.74% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

PHG

6.11%

Health Care Equipment & Supplies Industry

Max
29.44%
Q3
17.80%
Median
13.95%
Q1
8.73%
Min
-3.56%

PHG’s Operating Profit Margin of 6.11% is in the lower quartile for the Health Care Equipment & Supplies industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

BIO vs. PHG: A comparison of their Operating Profit Margin (TTM) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

SymbolBIOPHG
Return on Equity (TTM)4.58%-0.18%
Return on Assets (TTM)3.21%-0.08%
Net Profit Margin (TTM)12.49%0.90%
Operating Profit Margin (TTM)8.74%6.11%
Gross Profit Margin (TTM)53.00%43.85%

Financial Strength

Current Ratio (MRQ)

BIO

5.12

Life Sciences Tools & Services Industry

Max
4.76
Q3
2.77
Median
1.85
Q1
1.40
Min
0.43

BIO’s Current Ratio of 5.12 is exceptionally high, placing it well outside the typical range for the Life Sciences Tools & Services industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

PHG

1.26

Health Care Equipment & Supplies Industry

Max
4.90
Q3
3.05
Median
2.14
Q1
1.49
Min
0.86

PHG’s Current Ratio of 1.26 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

BIO vs. PHG: A comparison of their Current Ratio (MRQ) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

BIO

0.17

Life Sciences Tools & Services Industry

Max
1.75
Q3
0.83
Median
0.41
Q1
0.18
Min
0.00

Falling into the lower quartile for the Life Sciences Tools & Services industry, BIO’s Debt-to-Equity Ratio of 0.17 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

PHG

0.81

Health Care Equipment & Supplies Industry

Max
1.49
Q3
0.71
Median
0.45
Q1
0.14
Min
0.00

PHG’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.81. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

BIO vs. PHG: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

BIO

0.10

Life Sciences Tools & Services Industry

Max
29.61
Q3
23.24
Median
6.07
Q1
2.18
Min
-14.08

BIO’s Interest Coverage Ratio of 0.10 is a critical concern. A value below 1.0 means operating earnings are insufficient to cover interest expenses, indicating severe financial strain and high default risk.

PHG

1.41

Health Care Equipment & Supplies Industry

Max
58.29
Q3
25.56
Median
9.06
Q1
3.60
Min
-28.92

In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Interest Coverage Ratio of 1.41 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

BIO vs. PHG: A comparison of their Interest Coverage Ratio (TTM) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

SymbolBIOPHG
Current Ratio (MRQ)5.121.26
Quick Ratio (MRQ)3.390.81
Debt-to-Equity Ratio (MRQ)0.170.81
Interest Coverage Ratio (TTM)0.101.41

Growth

Revenue Growth

BIO vs. PHG: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

BIO vs. PHG: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

BIO

0.00%

Life Sciences Tools & Services Industry

Max
1.80%
Q3
0.78%
Median
0.37%
Q1
0.00%
Min
0.00%

BIO currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

PHG

0.00%

Health Care Equipment & Supplies Industry

Max
4.05%
Q3
1.76%
Median
0.71%
Q1
0.00%
Min
0.00%

PHG’s Dividend Yield of 0.00% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.

BIO vs. PHG: A comparison of their Dividend Yield (TTM) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

BIO

0.00%

Life Sciences Tools & Services Industry

Max
156.00%
Q3
65.73%
Median
23.81%
Q1
0.00%
Min
0.00%

BIO has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

PHG

0.42%

Health Care Equipment & Supplies Industry

Max
160.00%
Q3
72.47%
Median
27.49%
Q1
0.00%
Min
0.00%

PHG’s Dividend Payout Ratio of 0.42% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

BIO vs. PHG: A comparison of their Dividend Payout Ratio (TTM) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

SymbolBIOPHG
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.42%

Valuation

Price-to-Earnings Ratio (TTM)

BIO

24.37

Life Sciences Tools & Services Industry

Max
117.96
Q3
65.59
Median
37.26
Q1
27.51
Min
1.73

In the lower quartile for the Life Sciences Tools & Services industry, BIO’s P/E Ratio of 24.37 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

PHG

140.05

Health Care Equipment & Supplies Industry

Max
73.48
Q3
51.69
Median
34.31
Q1
25.74
Min
11.47

At 140.05, PHG’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

BIO vs. PHG: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

BIO

3.04

Life Sciences Tools & Services Industry

Max
12.46
Q3
6.70
Median
4.24
Q1
2.68
Min
0.73

BIO’s P/S Ratio of 3.04 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

PHG

1.26

Health Care Equipment & Supplies Industry

Max
9.53
Q3
5.26
Median
3.39
Q1
2.13
Min
0.00

In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s P/S Ratio of 1.26 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

BIO vs. PHG: A comparison of their Price-to-Sales Ratio (TTM) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

BIO

0.93

Life Sciences Tools & Services Industry

Max
7.99
Q3
4.69
Median
3.30
Q1
1.88
Min
1.02

BIO’s P/B Ratio of 0.93 is below the established floor for the Life Sciences Tools & Services industry. This may signal that the market is deeply pessimistic or has overlooked the company, potentially offering its asset base at a significant discount.

PHG

1.89

Health Care Equipment & Supplies Industry

Max
10.85
Q3
5.98
Median
3.48
Q1
2.43
Min
0.69

PHG’s P/B Ratio of 1.89 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

BIO vs. PHG: A comparison of their Price-to-Book Ratio (MRQ) against their respective Life Sciences Tools & Services and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

SymbolBIOPHG
Price-to-Earnings Ratio (TTM)24.37140.05
Price-to-Sales Ratio (TTM)3.041.26
Price-to-Book Ratio (MRQ)0.931.89
Price-to-Free Cash Flow Ratio (TTM)22.3714.66